Will magic mushrooms be the cure for the $300 billion mental health market? (w/ Jonathan Gilbert)

GreenStar Biosciences (CSE: GSTR) director and Eleusian Biosciences founder Jonathan Gilbert joins Small Caps to discuss the market potential of psychedelic medicine, specifically psilocybin mushrooms. Niv Dagan, executive director of Peak Asset Management, also joins the discussion on how psychedelics could revolutionise the mental health market and offer real solutions to modern day problems so many are facing. Eleusian Biosciences Corp is a Toronto based company focused on development of therapeutics for multiple pathological psychological diseases based on psilocybin plus N-Acetylycsteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mild traumatic brain injury/concussion (mTBI) with post-traumatic stress disorder (PTSD), or PTSD alone, using psilocybin and NAC. GreenStar Biosciences Corp will acquire 100% of Eleusian Biosciences Corp.